Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stelara Clears FDA; Different Mechanism of Action, But REMS Looks Similar To TNF Class

This article was originally published in The Pink Sheet Daily

Executive Summary

Centocor's newest anti-inflammatory biologic - ustekinumab - actually has a different mechanism than the TNF inhibitors, but FDA has the sponsor using a risk management program similar to existing TNF drugs.

You may also be interested in...

Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into

The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.

FDA To Centocor: Show Me The REMS

Ustekinumab “complete response” letter requests medication guide and communication plan, but not restricted distribution.

J&J’s Stelara Beats Enbrel In Psoriasis

New survey shows doctors are warming to another rival, Humira.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts